- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06135493
Prevention of Paclitaxel-induced Peripheral Neuropathy in Breast Cancer Patients
Efficacy of Losartan in the Prevention of Paclitaxel-induced Peripheral Neuropathy in Breast Cancer Patients.
Paclitaxel-induced peripheral neuropathy (PIPN) is one of the most dose-limiting side effects; it causes patients discomfort and pain and sometimes causes the termination of the chemotherapy cycles, leading to treatment failure. A lot of interventions have been tried to prevent PIPN, ensure complete administration of the chemotherapy cycles, and increase the survival rate. One of the promising interventions in the prevention of PIPN is Losartan. Losartan is an angiotensin receptor blocker (ARBs) and is used to treat hypertensive patients. There is strong evidence from different preclinical studies and retrospective cohort studies that Losartan has a neuroprotective effect.
The purpose of our study is to investigate the efficacy of Losartan in the prevention of peripheral neuropathy associated with Paclitaxel treatment in Breast Cancer patients.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Alaa Mahmoud Ahmed Shawqy, Bachelor's
- Phone Number: 01155935619
- Email: Aalaa.Mahmoud@fue.edu.eg
Study Locations
-
-
-
Cairo, Egypt
- Recruiting
- Breast Cancer Comprehensive Center of the National Cancer Institute, Cairo University
-
Contact:
- Farida Ali
- Phone Number: 01228188969
- Email: faridaali.nci@gmail.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Females older than 18 years diagnosed with biopsy-confirmed breast cancer (Early breast cancer eligible for adjuvant or neoadjuvant) who are scheduled to receive paclitaxel 80 mg/m2.
Exclusion Criteria:
- Known hypersensitivity to Losartan.
- Not Known Hypertensive patients
- Not Known Diabetic patients
- Treatment with Losartan/ARBs/ACE-I prior to the study.
- Previous neuropathy
- Renal impairment (Serum creatinine > 2 mg/dl)
- Significant liver disease: liver enzymes 2 folds the upper normal limit
- Metastatic breast cancer
- Pregnancy or lactation
- Taking other medication for neuropathic pain
- Significant Hypotension
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
No Intervention: Control arm
These patients will receive standard-of-care management for chemotherapy-induced nausea and vomiting
|
|
Experimental: Intervention arm
These patients will receive standard-of-care management for chemotherapy-induced nausea and vomiting plus losartan 100mg
|
Using losartan to prevent paclitaxel-induced peripheral neuropathy
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Development of paclitaxel-induced peripheral neuropathy
Time Frame: 12 weeks
|
Incidence of Development of paclitaxel-induced peripheral neuropathy
|
12 weeks
|
Grade of neuropathy
Time Frame: 12 weeks
|
Neuropathy grade according to NCI Common Terminology Criteria for Adverse Events
|
12 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Functional Assessment of Cancer Therapy/Gynecologic Oncology Group - Neurotoxicity (FACT/GOG-NTX)
Time Frame: 12 weeks
|
Patient quality of life will be assessed by Functional Assessment of Cancer Therapy/Gynecologic Oncology Group - Neurotoxicity (FACT/GOG-NTX)
|
12 weeks
|
Biomarker
Time Frame: 12 weeks
|
Level of Nerve growth factor (NGF) in Serum
|
12 weeks
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- REC-FPFUE-30/2023
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Peripheral Neuropathy Due to Chemotherapy
-
Medical College of WisconsinRecruitingPeripheral Neuropathy Due to ChemotherapyUnited States
-
Ain Shams UniversityNasser Institute For Research and TreatmentCompletedPeripheral Neuropathy Due to ChemotherapyEgypt
-
Mit Ghamr Oncology CenterRecruiting
-
Instituto Brasileiro de Controle do CancerUnknownPeripheral Neuropathy Due to ChemotherapyBrazil
-
Texas Woman's UniversityNot yet recruitingPeripheral Neuropathy Due to Chemotherapy
-
Radboud University Medical CenterErasmus Medical Center; Medisch Centrum LeeuwardenRecruitingCancer | Physical Activity | Toxicity Due to Chemotherapy | Systemic TreatmentNetherlands
-
Wellstat TherapeuticsApproved for marketing
-
Arash Asher, MDVoxxLifeRecruitingNeuropathy | Chemotherapy-induced Peripheral Neuropathy | Neuropathy;PeripheralUnited States
-
Academisch Medisch Centrum - Universiteit van Amsterdam...Leiden University Medical Center; Reinier de GraafRecruitingChemotherapy-induced Peripheral Neuropathy | CIPN - Chemotherapy-Induced Peripheral Neuropathy | Qutenza | DuloxetineNetherlands
-
Theodoros FoukakisKarolinska Institutet; Centre for Research and Technology Hellas (CERTH)RecruitingQuality of Life | Breast Cancer | Breast Neoplasms | Chemotherapy-induced Peripheral Neuropathy | Early-stage Breast Cancer | Non-Metastatic Breast Carcinoma | Polyneuropathy Due to Drugs | Polyneuropathy; DrugSweden
Clinical Trials on Losartan
-
Baker Heart and Diabetes InstituteWithdrawn
-
National Institute of Diabetes and Digestive and...Johns Hopkins UniversityTerminatedNAFLD - Nonalcoholic Fatty Liver DiseaseUnited States
-
Chinese PLA General HospitalTianjin TongRenTang Group Co., Ltd.UnknownProteinuria | GlomerulonephritisChina
-
University of South FloridaNational Cancer Institute (NCI)CompletedPrecancerous ConditionUnited States
-
Organon and CoTerminated
-
Vifor PharmaCompleted
-
Dong Wha Pharmaceutical Co. Ltd.Completed
-
EMSSuspended
-
University of MiamiNational Heart, Lung, and Blood Institute (NHLBI); Flight Attendant Medical...TerminatedCOPD | Chronic BronchitisUnited States